Middle East and Turkey Hemophilia Treatment Market, By Product Type, By Disease Indication, and By Country -

Description

Middle East And Turkey Hemophilia Treatment Market is estimated to be valued at USD 864.4 Mn in 2026 and is expected to reach USD 1,192.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 864.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.70%	2033 Value Projection:	USD 1,192.2 Mn

Hemophilia is rare disorder, in which the blood does not clot properly, and Bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood that results in constant bleeding for longer duration after an injury.

Market Dynamics

Increasing adoption of inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in March 2021, Takeda Pharmaceutical Company Limited., a pharmaceutical company, announced it had entered into a strategic partnership with Enzyre, developer of diagnostic technology, to accelerate the development of Enzyre's proprietary platform named Enzypad to enable patients to test their blood coagulationat their home.

Increasing adoption of organic growth strategies such product launches by key market players, in oder to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in November 2022, UniQure, a pharmaceutical company, announced the U.S. Food and Drug Administration approved the first gene therapy Hemgenix for the treatment of adults with hemophilia B that is currently used in factor IX prophylaxis therapy, or has current or historical life-threatening hemorrhage. Hemophilia B is a rare, lifelong bleeding disorder caused by a single gene defect that results in insufficient production of factor IX, a protein produced by the liver that aids in the formation of blood clots.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Turkey hemophilia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Middle East and Turkey hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey hemophilia treatment market

Detailed Segmentation:

Middle East and Turkey Hemophilia Treatment Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
Middle East and Turkey Hemophilia Treatment Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
Hemophilia A
Hemophilia B
Hemophilia C
Middle East and Turkey Hemophilia Treatment Market, By Country (Revenue, USD Mn, 2021 - 2033)
Turkey
Egypt
Israel
Saudi Arabia
UAE
Rest of Middle East
Company Profiles
Takeda Pharmaceutical Company Limited.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi S.A.
Octapharma AG
Swedish Orphan Biovitrum AB
Baxter
Biogen Inc.
Bayer AG
CSL Behring
Ferring B.V.
Pfizer, Inc.
Kedrion
Novo Nordisk A/S
Grifols S.A.
Sangamo Therapeutics, Inc.
Spark Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI3250

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Country
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
Product Launches
Merger, Acquisition, Collaborations
Regulatory Guideline and Compliances
Key Developments
PEST Analysis
Technology Landscape
PORTER's Analysis
Pricing Analysis

4. Middle East and Turkey Hemophilia Treatment Market, By Product Type, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Recombinant Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Plasma Derived Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antifibrinolytic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Desmopressin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Middle East and Turkey Hemophilia Treatment Market, By Disease Indication, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hemophilia A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Hemophilia B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Hemophilia C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Middle East and Turkey Hemophilia Treatment Market, By Country, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
Turkey
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
Egypt
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
Israel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
Saudi Arabia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
UAE
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
Rest of Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)

7. Competitive Landscape

Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kedrion
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Grifols S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sangamo Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Spark Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance

8. Section

Research Methodology
About Us